Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Third Quarter ended 30 September 2006 (Q3 2006) and Nine Months ended 30 September 2006.
Issuance Date: 26 October 2006
GSK reported strong performance driven by pharmaceutical sales growth, particularly in the US, and cost efficiencies. The company raised its full-year earnings guidance, increased its dividend, and announced a new share buy-back programme.
Key Financial Metrics
| Metric | Q3 2006 | Q3 2005 | CER Growth | 9M 2006 | 9M 2005 | CER Growth |
|---|---|---|---|---|---|---|
| Turnover | £5,642m | £5,471m | 7% | £17,266m | £15,753m | 9% |
| Operating Profit | £2,023m | £1,783m | 19% | £6,108m | £5,241m | 16% |
| Profit Before Tax | £2,022m | £1,753m | 21% | £6,089m | £5,126m | 18% |
| Profit After Tax | £1,426m | £1,253m | 19% | £4,293m | £3,665m | 16% |
| Earnings Per Share (EPS) | 24.7p | 21.3p | 21% | 74.5p | 62.8p | 18% |
| Operating Margin | 35.9% | 32.6% | +3.3 pts | 35.4% | 33.3% | +2.1 pts |
Cash Flow (Q3 2006): Net cash outflow from operating activities was £52m, primarily due to a £1.8 billion payment to settle a US transfer pricing dispute. Excluding this payment, operating cash flow exceeded routine needs.
Balance Sheet (30 Sep 2006): Net assets increased to £9,404m. Net debt increased to £2,118m (from £1,237m at year-end 2005) following the tax settlement payment.
Material Changes vs. Prior Period
- Pharmaceutical Sales: Up 7% to £4.9 billion. US sales grew 14% (benefiting from a £200m reversal of a rebate provision), while Europe was flat due to generic competition on Lamictal, Imigran, and Zofran.
- Consumer Healthcare: Sales up 4% to £766 million. Operating profit fell 19% due to lower profits on product disposals compared to the prior year.
- Cost Structure: SG&A costs were 10% lower year-over-year, driven by significantly reduced legal charges (£22m vs £190m in Q3 2005). R&D expenditure increased 11%.
- Key Product Performance:
- Seretide/Advair: +14% to £813m.
- Lamictal: +27% to £257m.
- Avandia family: +11% to £378m.
- Flonase: -59% due to generic competition.
Guidance, Outlook, and Risks
Guidance and Capital Allocation
- Earnings Guidance: Raised to mid-teens EPS percentage growth (CER terms) for full-year 2006 (previously ~12%).
- Dividends: Q3 interim dividend declared at 12p (up from 10p). Full-year 2006 dividend expected to be 48p (up from 44p).
- Share Buy-back: Announced a new £6 billion programme over three years, with £2 billion expected in the first 12 months.
Pipeline and Strategic Updates
- Acquisition: Proposed acquisition of CNS Inc. (Breathe Right, FiberChoice) for approx. $566 million.
- Approvals: FDA approved Coreg CR and FluLaval. Tykerb (breast cancer) filed in US/Europe. Cervarix (HPV vaccine) US filing expected by April 2007.
- Discontinuations: Development of Redona (diabetes) placed on hold; 270773 (sepsis) discontinued.
Risks and Contingencies
- Taxation: Settled US transfer pricing dispute (1989-2005) with a net cash cost of approx. $3.1 billion. Open tax issues remain in the UK, Japan, and Canada.
- Legal: Aggregate provision for legal disputes (excluding tax) is over £1.1 billion. Ongoing litigation includes patent challenges for Wellbutrin XL and Imitrex, and an EU anti-trust investigation regarding Seroxat.
- Currency: Adverse currency impact of 5% on Q3 EPS due to a weaker dollar and yen.
Investor Verification Checklist
- Tax Settlement Impact: Verify the final net cash cost of the US IRS settlement ($3.1 billion) and its impact on future liquidity and tax rates.
- Generic Competition: Monitor sales trends for Flonase, Lamictal, and Zofran as generic competition intensifies in Europe and the US.
- Pipeline Milestones: Track FDA approval dates for Tykerb, Cervarix, and Entereg, and the outcome of the ADOPT trial for Avandia.
- Acquisition Integration: Confirm regulatory clearance and closing date for the CNS Inc. acquisition.
- Legal Provisions: Review updates on the EU anti-trust investigation regarding Seroxat and patent litigation outcomes for Wellbutrin XL.